Forget Beyond Meat — Adaptive Biotechnologies just spiked 95% in its public trading debut, marking the year’s best post-IPO pop

CNBCChad Robins, the CEO of Adaptive Biotechnologies.

  • Adaptive Biotechnologies went public on Thursday, jumping 95% above its offer price at the open.
  • That marked the best post-IPO pop of the year for any company, on an offer-to-open basis.
  • The Seattle-based biotech, which provides tests used to diagnose and treat diseases, began trading shortly after noon Eastern Time under the ticker symbol “ADPT.”
  • Visit Markets Insider’s homepage for more stories.

Adaptive Biotechnologies went public on Thursday, jumping 95% above its IPO price at the open. It marked the best post-IPO pop of the year for any company, on an offer-to-open basis.

The Seattle-based company’s spike dethroned Crowdstrike – which jumped 87% at the open following its offering – for 2019’s best debut. Adaptive also outperformed Beyond Meat, which surged 84% at the open following its recent IPO.

Adaptive, which provides tests used to diagnose and treat diseases, is the latest in a long line of new biotechnology and healthcare issues to hit the public market this year.

This story is developing. Please refresh for updates.


A bonus just for you:


Click here to claim 30 days of access to Business Insider PRIME

Business Insider Emails & Alerts

Site highlights each day to your inbox.

Follow Business Insider Australia on Facebook, Twitter, LinkedIn, and Instagram.